Navigation Links
Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Date:3/1/2011

THE WOODLANDS, Texas, March 1, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Cowen and Company 31st Annual Health Care Conference in Boston on Monday, March 7, 2011 at 4:45 p.m. Eastern Time.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

A live webcast of the presentation will be available through Lexicon's corporate website at www.lexpharma.com.  An archived version of the presentation will be available for 30 days after the event.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
2. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
3. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
4. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
5. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
6. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
7. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
9. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
10. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
11. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... 2017  May is Stroke Awareness Month and Omron ... important methods to prevent a stroke: monitor and manage ... Control and Prevention, undetected and uncontrolled hypertension is a ... global leader in personal heart health technology, recently evolved ... attack and stroke and is advancing a national public ...
(Date:5/4/2017)... and SAN DIEGO , May ... Gynecologists (ACOG) 2017 Annual Clinical and Scientific Meeting— OBP ... illuminating medical devices, today announced the launch of a ... OfficeSPEC and ER-SPEC vaginal specula. ... of extra-small and extra-large sizes makes OBP Medical,s line ...
(Date:5/3/2017)...  Kalorama Information notes that transplant diagnostics is ... and this is projected to continue to 2021. ... or bone marrow transplants require histocompatibility between the ... this task. This according to a new report ... various PCR-based methodologies, Sanger sequencing and NGS used ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... Myers Jackson is ... has the ability to sell luxury homes anywhere on the planet. The luxury home ... side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant Technology, a ... portfolio. ExtraHop delivers an analytics-first approach, layered with machine learning, that provides real-time ... datacenter to the cloud to the edge. Through the new partnership, customers get ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... City (PRWEB) , ... May 23, 2017 , ... ... Population Health and Clinical Integration company, announced today that its iClinic V12.2 ... Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... in North Carolina have remained steady since 2009, according to a Workers Compensation ... , The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition ...
Breaking Medicine News(10 mins):